Skip to content

US · GRAL · BIOTECHNOLOGY

GRAIL Inc. (GRAL) intrinsic value and stock valuation

$99.25as of 2026-11-21 · Mkt cap 3.18B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GRAIL Inc. DCF and intrinsic value

InvestorsCraft values GRAL with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from GRAL’s statements →

GRAIL Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Menlo Park, CA 94025 grail.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$147.2M
20182025
Net income
-$-408.35M
20182025
Free cash flow
-$-299.01M
20182025
Total equity
$2.58B+35.6% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$147.2M$125.6M$93.1M$55.6M$14.6M
Operating income-$-534.16M-$-2.19B-$-1.52B-$-5.44B-$-1.27B
Net income-$-408.35M-$-2.03B-$-1.47B-$-5.4B-$-1.25B
EPSd-$-11.11M-$-63.54M-$-47.2M-$-173.88M-$-40.19M
Operating cash flow-$-299.01M-$-577.16M-$-595.8M-$-561.31M-$-688.13M
Capital expenditure-$-910K-$-5.21M-$-12.89M-$-22.86M-$-69.93M
Free cash flow-$-299.01M-$-582.36M-$-608.69M-$-584.17M-$-758.06M
Total assets$2.92B$2.98B$4.56B$5.6B$9.74B
Total debt$98M$68.1M$84.4M$96M$110.6M
Net debt-$-151.72M-$-146.09M-$-12.88M-$-145.59M-$-110.6M
Total equity$2.58B$2.5B$3.65B$4.65B$9.43B
Cash and short-term investments$904.4M$763.5M$97.3M$241.6M$221.2M
Income statement
20252024202320222021
Revenue$147.2M$125.6M$93.1M$55.6M$14.6M
Cost of revenue$209.8M$203.6M$188.7M$172M$114.6M
Gross profit-$-62.57M-$-78.02M-$-95.61M-$-116.45M-$-100M
Research and development expenses$195.8M$322.4M$338.8M$329.6M$460.2M
Selling, general and administrative expenses$275.8M$367.8M$362.6M$296.4M$234.1M
Other expenses$0.00$1.42B$718.5M$4.7B$471.1M
Operating expenses$471.6M$2.11B$1.42B$5.33B$1.17B
Cost and expenses$681.3M$2.31B$1.61B$5.5B$1.28B
Interest income$28.7M$26.7M$7.95M$1.74M$330K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$156.3M$158.1M$158.7M$154.8M$58.5M
Ebitda-$-378.16M-$-610.17M-$-638.22M-$-587.7M-$-1.21B
Operating income-$-534.16M-$-2.19B-$-1.52B-$-5.44B-$-1.27B
Total other income/expenses, net-$-340K$26.8M$7.75M$1.5M$90K
Income before tax-$-534.5M-$-2.16B-$-1.51B-$-5.44B-$-1.27B
Income tax expense-$-126.15M-$-135.36M-$-41.95M-$-42.29M-$-17.48M
Net income-$-408.35M-$-2.03B-$-1.47B-$-5.4B-$-1.25B
Weighted average shares outstanding$36.8M$31.9M$31.1M$31.1M$31.1M
Weighted average diluted shares outstanding$36.8M$31.9M$31.1M$31.1M$31.1M
Balance sheet
20252024202320222021
Cash and short-term investments$904.4M$763.5M$97.3M$241.6M$221.2M
Net receivables$18.3M$24.6M$22.4M$18.6M$6.88M
Inventory$16M$18.6M$21.7M$19.8M$0.00
Total current assets$953.9M$819.9M$156.1M$295.6M$242.7M
Property, plant and equipment, net$103.9M$135.4M$169.4M$198.7M$216.4M
Goodwill and intangible assets$1.85B$2.02B$3.58B$4.43B$9.27B
Long-term investments$6.97M$0.00$4.22M$4.53M$0.00
Total non-current assets$1.97B$2.16B$4.4B$5.31B$9.5B
Total assets$2.92B$2.98B$4.56B$5.6B$9.74B
Accounts payable$2.08M$4.84M$19.7M$17.5M$17.7M
Short-term debt$11.7M$13.3M$14.8M$13.3M$13.8M
Deferred revenue$0.00$1.6M$0.00$0.00$0.00
Total current liabilities$79.7M$76.9M$163.6M$134.9M$97.9M
Long-term debt$86.3M$54.9M$69.6M$82.7M$96.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$264.5M$403M$747.1M$821M$209.5M
Capital lease obligations$43.2M$68.1M$69.6M$82.7M$110.6M
Total liabilities$344.2M$479.9M$910.7M$955.9M$307.4M
Common stock$40K$30K$11.4B$11B$10.3B
Retained earnings-$-10.21B-$-9.8B-$-7.78B-$-6.31B-$-911.54M
Accumulated other comprehensive income (loss)$2.65M$1.45M$1.07M$890K$310K
Total equity$2.58B$2.5B$3.65B$4.65B$9.43B
Total investments$661.7M$549.2M$4.22M$4.53M$0.00
Total debt$98M$68.1M$84.4M$96M$110.6M
Net debt-$-151.72M-$-146.09M-$-12.88M-$-145.59M-$-110.6M
Cash flow statement
20252024202320222021
Net income-$-408.35M-$-2.03B-$-1.47B-$-5.4B-$-1.25B
Depreciation and amortization$156.3M$158.1M$158.7M$154.8M$58.5M
Stock-based compensation$58.3M$86.1M$97.2M$75.7M$681.9M
Change in working capital$12.4M-$-24.28M$7.72M-$-14.46M$21.6M
Accounts receivable$1.69M-$-3.37M-$-1.38M-$-8.68M-$-6.88M
Inventory$2.62M$3.07M-$-1.94M-$-14.08M-$-5.67M
Accounts payable-$-2.73M-$-14.63M$2.89M$2.34M$1.3M
Net cash provided by operating activities-$-299.01M-$-577.16M-$-595.8M-$-561.31M-$-688.13M
Investments in property, plant and equipment-$-910K-$-5.21M-$-12.89M-$-22.86M-$-69.93M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-85.05M-$-551.01M-$-12.89M-$-22.86M$344.8M
Common stock issued$423.3M$0.00$0.00$0.00$5.98M
Common stock repurchased$0.00$0.00$0.00$0.00-$-170K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$423.3M$1.24B$463.8M$604.8M$394.7M
Net change in cash$39.1M$116.1M-$-144.62M$20.1M-$-143.19M
Cash at end of period$256.7M$217.6M$101.5M$246.1M$0.00
Operating cash flow-$-299.01M-$-577.16M-$-595.8M-$-561.31M-$-688.13M
Capital expenditure-$-910K-$-5.21M-$-12.89M-$-22.86M-$-69.93M
Free cash flow-$-299.01M-$-582.36M-$-608.69M-$-584.17M-$-758.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GRAIL Inc.

        GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

        CEO
        Joshua J. Ofman
        Employees
        910
        Beta
        3.22

        Explore

        Frequently asked questions

        What is the intrinsic value of GRAIL Inc. (GRAL)?

        GRAIL Inc. (GRAL) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GRAL undervalued?

        GRAL trades at a price of $99.25 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.